204 related articles for article (PubMed ID: 23559153)
1. Phase II study on lapatinib in advanced EGFR-positive chordoma.
Stacchiotti S; Tamborini E; Lo Vullo S; Bozzi F; Messina A; Morosi C; Casale A; Crippa F; Conca E; Negri T; Palassini E; Marrari A; Palmerini E; Mariani L; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2013 Jul; 24(7):1931-1936. PubMed ID: 23559153
[TBL] [Abstract][Full Text] [Related]
2. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.
Stacchiotti S; Morosi C; Lo Vullo S; Casale A; Palassini E; Frezza AM; Dinoi G; Messina A; Gronchi A; Cavalleri A; Venturelli E; Morelli D; Pilotti S; Collini P; Brich S; Tamborini E; Mariani L; Casali PG
Cancer; 2018 Oct; 124(20):4056-4063. PubMed ID: 30216418
[TBL] [Abstract][Full Text] [Related]
3. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
Bozzi F; Manenti G; Conca E; Stacchiotti S; Messina A; Dagrada G; Gronchi A; Panizza P; Pierotti MA; Tamborini E; Pilotti S
Neuro Oncol; 2014 Jan; 16(1):72-80. PubMed ID: 24366975
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of imatinib in advanced chordoma.
Stacchiotti S; Longhi A; Ferraresi V; Grignani G; Comandone A; Stupp R; Bertuzzi A; Tamborini E; Pilotti S; Messina A; Spreafico C; Gronchi A; Amore P; Vinaccia V; Casali PG
J Clin Oncol; 2012 Mar; 30(9):914-20. PubMed ID: 22331945
[TBL] [Abstract][Full Text] [Related]
8. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Thallinger C; Lang I; Kuhar CG; Bartsch R; Singer CF; Petruzelka L; Melichar B; Knittelfelder R; Brodowicz T; Zielinski C
BMC Cancer; 2016 Feb; 16():121. PubMed ID: 26887956
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
de Souza JA; Davis DW; Zhang Y; Khattri A; Seiwert TY; Aktolga S; Wong SJ; Kozloff MF; Nattam S; Lingen MW; Kunnavakkam R; Stenson KM; Blair EA; Bozeman J; Dancey JE; Vokes EE; Cohen EE
Clin Cancer Res; 2012 Apr; 18(8):2336-43. PubMed ID: 22371453
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.
Launay SG; Chetaille B; Medina F; Perrot D; Nazarian S; Guiramand J; Moureau-Zabotto L; Bertucci F
BMC Cancer; 2011 Oct; 11():423. PubMed ID: 21970335
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.
Schuetze SM; Bolejack V; Choy E; Ganjoo KN; Staddon AP; Chow WA; Tawbi HA; Samuels BL; Patel SR; von Mehren M; D'Amato G; Leu KM; Loeb DM; Forscher CA; Milhem MM; Rushing DA; Lucas DR; Chugh R; Reinke DK; Baker LH
Cancer; 2017 Jan; 123(1):90-97. PubMed ID: 27696380
[TBL] [Abstract][Full Text] [Related]
14. Imatinib in advanced chordoma: A retrospective case series analysis.
Hindi N; Casali PG; Morosi C; Messina A; Palassini E; Pilotti S; Tamborini E; Radaelli S; Gronchi A; Stacchiotti S
Eur J Cancer; 2015 Nov; 51(17):2609-14. PubMed ID: 26283036
[TBL] [Abstract][Full Text] [Related]
15. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Garcia AA; Sill MW; Lankes HA; Godwin AK; Mannel RS; Armstrong DK; Carolla RL; Liepman MK; Spirtos NM; Fischer EG; Leslie KK
Gynecol Oncol; 2012 Mar; 124(3):569-74. PubMed ID: 22037316
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Leslie KK; Sill MW; Lankes HA; Fischer EG; Godwin AK; Gray H; Schilder RJ; Walker JL; Tewari K; Hanjani P; Abulafia O; Rose PG
Gynecol Oncol; 2012 Nov; 127(2):345-50. PubMed ID: 22885469
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
Vidal L; Tsao MS; Pond GR; Cohen EE; Cohen RB; Chen EX; Agulnik M; Hotte S; Winquist E; Laurie S; Hayes DN; Ho J; Dancey J; Siu LL
Head Neck; 2009 Aug; 31(8):1006-12. PubMed ID: 19309723
[TBL] [Abstract][Full Text] [Related]
18. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Harrington K; Berrier A; Robinson M; Remenar E; Housset M; de Mendoza FH; Fayette J; Mehanna H; El-Hariry I; Compton N; Franklin N; Biswas-Baldwin N; Lau M; Legenne P; Kumar R
Eur J Cancer; 2013 May; 49(7):1609-18. PubMed ID: 23265705
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
Finn RS; Press MF; Dering J; Arbushites M; Koehler M; Oliva C; Williams LS; Di Leo A
J Clin Oncol; 2009 Aug; 27(24):3908-15. PubMed ID: 19620495
[TBL] [Abstract][Full Text] [Related]
20. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.
Liu C; Jia Q; Wei H; Yang X; Liu T; Zhao J; Ling Y; Wang C; Yu H; Li Z; Jiao J; Wu Z; Yang C; Xiao J
Lancet Oncol; 2020 Sep; 21(9):1244-1252. PubMed ID: 32888455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
